Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07323524 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dapagliflozin in Active Lupus Nephritis

Study acronym: Dapa-Active LN
StatusRecruiting
PhasePhase 4
Started2026-05-19
View on ClinicalTrials.gov ↗

Amendment history

2026-05-21
Study Status, Contacts/Locations v4
Recruitment opened
Start dateestimated 2026-06-01→confirmed 2026-05-19
Study sitesdetails revised at 2 of 2 sites
2026-04-27
Study Status v3
Start date2026-02-01→2026-06-01
2026-02-06
Study Status, Contacts/Locations v2
Re-verified, no change to tracked fields
2026-01-20
Study Status, Contacts/Locations v1
Study sites0→2
2026-01-06
Original filing
Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that predominately impacts young people and can lead to kidney failure. Sodium-glucose co-transporter-2 inhibitors, including dapagliflozin, are known to improve outcomes for people with other causes of chronic kidney disease. This pilot and feasibility randomized clinical trial will test the use of dapagliflozin versus placebo in addition to standard of care treatment for patients with early and active lupus nephritis, a group who has not been included in past trials.
Trial Details
NCT Number NCT07323524
Lead Sponsor Brigham and Women's Hospital
Collaborators: Massachusetts General Hospital
Conditions Lupus Nephritis (LN)
Enrollment 33 participants
Start Date 2026-05-19
Primary Completion 2029-07 (estimated)
Study Completion 2030-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-26